Fenofibric acid

Catalog No.S4527 Batch:S452702

Technical Data

Formula	C₁₇H₁₅ClO₄
Molecular Weight	318.75	CAS No.	42017-89-0
Solubility (25°C)*	In vitro	DMSO	64 mg/mL (200.78 mM)
		Water	Insoluble
		Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

Fenofibric acid (NSC 281318, Trilipix, FNF acid) is a fibrate that acts as a lipid-lowering agent, decreasing low-density lipoprotein cholesterol and triglycerides.

Targets

PPARα ^[1]

In vitro

Fibric acids, active forms of fibrate drugs and activators of peroxisome proliferator-activated receptor-alpha (PPARα), are also known for an HDL-raising effect. Fibric acids enhance fatty acid catabolism and accordingly reduce plasma lipid level, predominantly triglyceride (TG). Fenofibric acid increases the expression of ABCA1 and apoA-I–mediated HDL production. The effect on ABCA1 expression was through the enhancement of the transcription of the ABCA1 gene being dependent on LXR^[1].

In vivo

Fenofibric acid attenuates aberrant increases of circulating EPC(Endothelial Progenitor Cells) in OIR mice. Inhibitory effect of Fenofibric acid on EPC mobilization in the OIR model is PPARα-dependent.Fenofibric acid Inhibits hypoxia-induced retinal EPC increase in a PPARα-dependent manner. Fenofibric acid decreases CXCR4-positive EPC in the circulation, downregulates the serum SDF-1 level and suppresses HIF-1a and SDF-1 overexpression in the retina^[1].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines RAW264 cells; THP-1 cells Concentrations 0-200 μmol/L Incubation Time 48 h Method PPAR activators fenofibric acid is dissolved in DMSO and added to the culture medium containing 0.2% BSA. RAW264 cells are washed with PBS and cultured an additional 48 hours in the presence of fenofibric acid in DMEM/F-12(1:1) medium containing 2% TCM and 0.2% BSA. During the last 24 hours of the drug treatment, 300 mol/L of dibutyryl cAMP and apoA-I (10 μg/mL) are added to the medium. THP-1 cells are also treated with the compound and apoA-I in 0.2% BSA-RPMI 1640 medium and 0.1% BSA-MEM. Cholesterol and choline-phospholipid released into the medium by apoA-I are determined enzymatically. Adherent cells are dissolved in 0.1 N NaOH for protein determination by bicinchoninic acid protein assay system.
Animal Study:^{^[2]}	Animal Models C57BL/6J; PPARa-/- mice Dosages 10 mg/kg Administration i.p.

Cell Assay:^{^[1]}

Cell lines
RAW264 cells; THP-1 cells
Concentrations
0-200 μmol/L
Incubation Time
48 h
Method
PPAR activators fenofibric acid is dissolved in DMSO and added to the culture medium containing 0.2% BSA. RAW264 cells are washed with PBS and cultured an additional 48 hours in the presence of fenofibric acid in DMEM/F-12(1:1) medium containing 2% TCM and 0.2% BSA. During the last 24 hours of the drug treatment, 300 mol/L of dibutyryl cAMP and apoA-I (10 μg/mL) are added to the medium. THP-1 cells are also treated with the compound and apoA-I in 0.2% BSA-RPMI 1640 medium and 0.1% BSA-MEM. Cholesterol and choline-phospholipid released into the medium by apoA-I are determined enzymatically. Adherent cells are dissolved in 0.1 N NaOH for protein determination by bicinchoninic acid protein assay system.

Animal Study:^{^[2]}

Animal Models
C57BL/6J; PPARa-/- mice
Dosages
10 mg/kg
Administration
i.p.

References

Selleck's Fenofibric acid has been cited by 3 publications

Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [ J Immunother Cancer, 2024, 12(11)e009805]	PubMed: 39581704
Peroxisome Proliferator-Activated Receptor α Activation Protects Retinal Ganglion Cells in Ischemia-Reperfusion Retinas [ Front Med (Lausanne), 2021, 8:788663]	PubMed: 35004756
Immediate-released pelletized solid dispersion containing fenofibrate: Formulation, in vitro characterization, and bioequivalence studies in experimental beagle dogs. [ Int J Pharm, 2019, 570:118661]	PubMed: 31491482

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.